Trials / Completed
CompletedNCT03983031
Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)
Rituximab - Immunotherapy for Obsessive-compulsive Disorder: An Open Pilot Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Region Örebro County · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.
Detailed description
Immunological factors may be determinants for some psychiatric disorders, thus immunomodulation may be helpful. Rituximab (antibodies against CD20, cluster of differentiation), a standard treatment for multiple sclerosis, is an anti-inflammatory drug, hitherto not tested for psychiatric disorders. The aim of this study is to investigate whether the psychiatric symptoms of treatment-resistant adult psychiatric patients, diagnosed with obsessive-compulsive disorder (OCD), are significantly improved after treatment with rituximab. The investigator's purpose is to implement recent insights from "Immunopsychiatry" to find efficacious, but still tolerable treatment for these patients. This is a single-site, 20-week, open pilot, add-on treatment as usual, trial, where the patients will be followed for 1 year. Rituximab will be administered with one single dose of 1000 mg. Investigators will analyse inflammatory and metabolic biomarkers in relation to the primary outcome, treatment response (defined as clinically relevant reduction in the validated measure Y-BOCS). Other outcomes are "much" or "very much improved" on Clinical Global Impression - Improvement scale (CGI-I) and change in Personal and Social Performance Scale measuring overall disability.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Infusion |
Timeline
- Start date
- 2019-08-08
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2019-06-12
- Last updated
- 2022-05-10
Locations
2 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT03983031. Inclusion in this directory is not an endorsement.